A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the proposal, as well as a concession for the biopharma industry on first-in-human studies in PDUFA reauthorization negotiations with FDA. The analysts also discuss the latest pair of billion-dollar biotech deals: Gilead's $3.2 billion takeout of a...
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Ep. 362 - AACR: Data and de-risking
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.